The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy
Launched by BARTS & THE LONDON NHS TRUST · Aug 10, 2018
Trial Information
Current as of June 01, 2025
Completed
Keywords
ClinConnect Summary
The NITRATE-CIN trial is a single-centre, randomised double-blinded placebo-controlled trial, which plans to recruit, over a period of 2 years, 640 patients presenting with acute coronary syndromes (ACS) who are at risk of CIN.
Patients will be randomised to either dietary inorganic nitrate therapy or placebo.
The primary endpoint will be the development of CIN (KDIGO criteria). A key secondary endpoint will be whether nitrate therapy impacts upon persistent renal impairment over a 3-month follow-up period. Additional secondary endpoints include the measurement of serum renal biomarkers (...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients undergoing coronary angiography+/-Percutaneous Coronary Intervention (PCI) for NSTE-ACS
- 2. Requirement for CIN prophylaxis as per Barts Heart Centre Criteria for CIN prophylaxis:
- • eGFR\<60ml/min OR 2 of the following: diabetes, liver failure (cirrhosis), age \> 70yr, exposure to contrast in last 7 days, heart failure (or LVEF\<40%), concomitant renally active drugs (ACEi, ARB, NSAIDs, aminoglycosides, diuretics)
- • 3. Aged \>18
- • 4. Patients able and willing to give their written informed consent.
- Exclusion Criteria:
- • 1. ST segment myocardial infarction undergoing Primary PCI.
- • 2. Patients with eGFR\<30ml/min or on renal replacement therapy
- • 3. Subjects presenting with cardiogenic shock (systolic blood pressure \<80 mmHg for \>30 minutes, or requiring inotropes or emergency intra aortic balloon pump for hypotension treatment) or cardiopulmonary resuscitation
- • 4. Current life-threatening condition other than vascular disease that may prevent a subject completing the study.
- • 5. Use of an investigational device or investigational drug within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of study medication.
- • 6. Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures).
- • 7. Severe acute infection
- • 8. Pregnancy
- • 9. Breast-feeding mothers.
- • 10. Any Inclusion Criteria not met
About Barts & The London Nhs Trust
Barts and The London NHS Trust is a leading healthcare organization in the United Kingdom, renowned for its commitment to delivering high-quality clinical care, research, and education. As a prominent sponsor of clinical trials, the Trust is dedicated to advancing medical knowledge and improving patient outcomes through innovative research initiatives. With a focus on patient safety and ethical standards, Barts and The London NHS Trust collaborates with multidisciplinary teams to explore cutting-edge therapies and interventions across various medical fields, ensuring that trial participants receive the highest level of care and support throughout their involvement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Amrita Ahluwalia, PhD
Principal Investigator
Queen Mary University of London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials